New malaria vaccine trial aims for safer, stronger protection
NCT ID NCT06735209
First seen Sep 30, 2025 · Last updated May 20, 2026 · Updated 29 times
Summary
This early-stage study tests a new malaria vaccine made from genetically weakened parasites. The goal is to see if it is safe and can train the immune system to fight malaria without causing the disease. About 22 healthy adults who have never had malaria will receive the vaccine or a placebo and then be exposed to the malaria parasite in a controlled setting. The study focuses on safety and whether the vaccine can prevent infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Washington - Virology Research Clinic
Seattle, Washington, 98104, United States
Conditions
Explore the condition pages connected to this study.